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Summary 
IgA Nephropathy (IgAN) is the most common worldwide primary glomerulonephritis with a strong 
autoimmune component . The disease shows variability in both clinical phenotypes and endpoints, and can 
be potentially subdivided into more homogenous subtypes through the identification of specific molecular 
biomarkers. This review focuses on the role of -omics in driving the identification of potential molecular 
subtypes of the disease through the integration of multi-level data from genomics, transcriptomics, 
epigenomics, proteomics and metabolomics. First, the identification of molecular biomarkers, including 
mapping of the full spectrum of common and rare IgAN risk alleles, could permit a more precise 
stratification of IgAN patients. Second, the analysis of transcriptomic patterns and their modulation by 
epigenetic factors like miRNAs have the potential to increase our understanding in the pathogenic 
mechanisms of the disease. Third, the specificity of urinary proteomic and metabolomic signatures and the 
understanding of their functional relevance may contribute to the development of new non-invasive 
biomarkers for a better molecular characterization of the renal damage and its follow-up. All these 
approaches can give information for targeted therapeutic decisions and will support novel clinical decision 
making. In conclusion, we offer a framework of omic studies and outline barriers and potential solutions 
that should be used for improving the diagnosis and treatment of the disease. The ongoing decade is 
exploiting novel high-throughput molecular technologies and computational analyses for improving the 
diagnosis (precision nephrology) and treatment (personalised therapy) of the IgAN subtypes. 
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Introduction  
IgA Nephropathy (IgAN) is the most common primary glomerulonephritis worldwide [1, 2] that develops 
mainly  in the 2nd and 3rd decade of life and 40% of IgAN cases reach end-stage kidney disease (ESKD) after 
20 years from the biopsy-proven diagnosis implying a great socio-economical burden.[3, 4]   In this review, 
we describe the results of omics studies carried out in IgAN patients. We move from genomic studies 
focusing on common and rare variants linked to the disease, to transcriptomics carried out on circulating 
immune cells and kidney biopsy specimens and then to epigenomics, proteomics and metabolomics . 
Finally, we suggest an integrative approach for developing biological networks and identify potential 
diagnostic biomarkers for Precision Nephrology and Personalized Therapy. 
 
1.1 GENOMICS 
Two main genome wide genetic approaches have been used in the study of this complex disease: Genome 
Wide Association Studies (GWAS) and Next Generation Sequencing (NGS).  
1.1.1 Common Variants 
The GWAS conducted on IgAN have identified several common variants that clearly show a strong 
participation of the Human Leukocyte Antigen (HLA) system, genes involved in innate immunity, and other 
loci summarized in Supplementary Table 1. Seven Single-Nucleotide Polymorphisms (SNPs) identified 
through GWAS were used for constructing a genetic risk score, which explained 4.7% of overall IgAN risk.[5] 
This score was integrated with other 8 recently associated SNPs,[6] but it cumulatively explains only 5.37% 
of disease risk (http://www.columbiamedicine.org/divisions/gharavi/calc_genetic.php). In summary, IgAN 
risk loci identified through GWAS i) are common to other inflammatory and immune-mediated diseases, ii) 
explain a proportion of the disease risk worldwide, iii) contribute to the geographic variation in disease 
prevalence, iv) confirm the polygenic and multiple-susceptibility-gene nature of IgAN. Future studies are 
needed to evaluate if these GWAS signals are effectively generated by causative common variants or due to 
rare variants in linkage disequilibrium with the common ones. Direct sequencing of the associated regions 
may lead to a finer mapping of these disease-related loci, as seen for example in chronic obstructive 
pulmonary disease. [7] 
 Very recently two quantitative GWAS have identified two loci, in core 1, β1-3-galactosyltransferase-1 
(C1GALT1) and C1GALT1 Specific Chaperone 1 (C1GALT1C1-cosmc)[8, 9] providing novel insights into the 
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genetic regulation of O-glycosylation and providing evidence that also common genetic variations can 
influence O-glycosylation. 
Copy Number Variants (CNVs) in IgAN have been reported in complement Factor H Related proteins(CFHR1, 
CFHR3) [10, 11]  and have been associated with decreased IgAN risk (supplementary Table 2). CNVs were 
also found enriched in the linked 17q12-22 locus [12, 13] and in the Toll Like Receptor 9 (TLR9) gene where 
its potential role in disease progression was confirmed.[13] A lower copy number of three variants within 
the defensin highly variable locus correlated with renal dysfunction, increased serum IgA1 and Gd-IgA1.[14, 
15] 
1.1.2 Rare variants 
Rare variants, usually found in the frequency range between 0.1% and 1%, are more likely to have a 
stronger effect in complex diseases compared to common variants. Three A Whole Exome Sequencing 
(WES) studies have been performed on IgAN (Supplementary Table 3).y performed in Chinese with familial 
IgAN The first study evidenced seven common co-segregating deleterious variants within four genes 
(CARD8, DEFA4; MYCT1, ZNF543).[16] Another The second WES study performed on two affected 
individuals and an unaffected familial control from a large Sicilian family with multiple affected 
individuals,17 identified a novel missense variant in the Sprouty RTK Signaling Antagonist 2 (SPRY2) gene 
that segregated in all IgAN affected individuals.[17] Functional analysis of the variant in B lymphoblastoid 
cell lines from affected members linked the SPRY2 mutation showed the inhibition of the MAPK/ERK 
pathway. Recently, a combined linkage analysis and exome sequencing methodology has been successfully 
applied for pinpointing specific causative variants involved in familial goiter.[18] A similar procedure has 
been carried out by Cox et al[19] in the last IgAN IgAN study and their results support  a polygenic and a 
multiple-susceptibility-gene model for familial IgAN.[19] Evident connections with previous gene expression 
studies were found, but further studies are needed to understand whether these variants can effectively 
disrupt gene function and validate their causality in contributing to IgAN phenotype. Furthermore, these 
studies must be replicated in other independent cohorts of IgAN patients to confirm the validity of the 
results. 
To date several efforts have been made to identify susceptibility variants, but NGS data for the 
identification of rare variants within IgAN GWAS areas has never been done. This strategy has been recently 
applied in the study of age-related macular degeneration in which rare causative coding variants were 
pinpointed within known associated genetic loci and could represent an innovative and promising approach 
for IgAN.[20] Association testing deployed in parallel or in combination to familial linkage could represent  
another innovative strategy for the identification and characterization of a full range of disease-
susceptibility variants [21, 22] as seen in hearing impairment  and cardiomyopathy .[21-24]  
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1.2 TRANSCRIPTOMICS 
Transcriptome is considered the gene signature leading to a phenotype that is possibly influenced by 
genetic determinants. Specific gene expression patterns have been found in IgAN patients' blood cells. 
(Supplementary Table 4). An aberrant modulation of genes belonging to the WNT-β-catenin and PI3K/AKT 
pathways was found in peripheral blood leukocytes (PBL) IgAN patients.[25] Monocytes were principally 
involved in the altered WNT signaling pathway and an expansion of the non-classical CD16+ monocyte 
subset characterized by an enhanced apoptotic potential was demonstrated.[26] Moreover, 
transcriptomics was used to analyze gross hematuria episodes in concomitance to mucosal infections,[26]  
an important time point for IgAN.[27, 28]  Differently regulated genes during the gross hematuria episode 
were principally involved in interferon signaling and antigen presentation.[28] This network showed an up-
regulation of genes involved in the immune-proteasome pathway and based on a series of additional 
experimental approaches, C-X3-C Motif Chemokine Receptor 1 (CX3CR1) and its ligand fractalkine were 
found to promote macroscopic hematuria in IgAN patients.(77)  An important limitation of all these 
experimental approaches is that gene expression data have not been integrated with genome wide 
genotype data. This integration could be useful for the identification of expression quantitative trait loci 
(eQTL) giving a direct genetic explanation of aberrant gene expression data, useful for translational 
medicine.[29]  
Most transcriptomic findings have been obtained from complex starting material i.e whole blood, which is 
made up of different cell lineages. Future studies should propend towards the use of cell sorting 
technologies for analyzing the transcriptomic profile of specific cell populations or single cell analysis may 
give novel insights into health and disease status.[30]  These novel technological approaches may help to 
obtain cell-lineage specific expression data from IgA1 secreting cells, giving important insights into the 
pathogenic  mechanisms involved in the disease.   
The renal damage in IgAN is caused by mesangial deposition of polymeric IgA1 and or IgA1-IgG immune 
complexes at glomerular level leading to oversynthesis of extracellular matrix (ECM). Since alterations in 
mRNA levels could precede the histological damage, transcriptomics in kidney tissue might identify gene 
expression profiles involved in the development and progression of renal damage.  
Investigators focused their attention on the gene expression of isolated glomeruli or tubulointerstitial 
tissue from IgAN patients' kidney biopsies.[31, 32] They observed an increased expression of some 
proteoglycans directly involved in renal damage and suggested their potential role as prognostic 
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biomarkers and highlighted an 11 transcript proteinuria signature in the tubulo-interstitial 
compartement.[31, 32] Differently expressed genes in microdissected glomeruli with endocapillary 
proliferation were involved in innate immune response, classical complement pathway activation and 
matrix turnover.[33] (supplementary Table 5) Interestingly, the in-silico study demonstrated that the 
aberrantly expressed genes characterizing endocapillary proliferation were responsive to the combined 
corticosteroid-resveratol therapy.[33] Studies on the isolated tubulointerstitial compartment showed a 
reduced expression of VEGF and an enhanced expression of Decorin. The latter correlated positively with 
proteinuria[31] and was included in an 11-transcript proteinuria signature[32]. A subsequent study 
demonstrated that altered expressed genes were responsive to some organic substances such as 
doxorubicin and thapsigargin[34] (see supplementary Table 5).  
Data from these studies indicate that (i) glomerular and tubulointerstitial gene expressions are 
independent; (ii) some genes involved in specific pathways are responsive to drugs.  Gene expression data 
from isolated glomeruli or tubules are not correlated to the extent of renal damage but it's a sterile 
description of up and down-regulated genes. Future studies should be performed on the entire tissue as 
whole since kidney disease involves all renal compartments globally and simultaneously. In particular, gene 
expression studies will need to be performed on well characterized kidney biopsy specimens that have 
been accurately  scored with the new reproducible MEST-C classification system.[35] In this way specific 
gene expression changes that characterize active renal lesions (E and C) that are more responsive to 
immunosuppressive therapy compared to chronic lesions (S and T) wiil be identified. Furthermore, 
differences in gene expression linked to the degree of histologic renal damage have yet to be evaluated. 
This information is important because glomerular lesions are always associated with tubulointerstitial 
damage during the progression of renal damage.  
The emerging transcriptomic methodology not deployed in the study of IgAN is RNAseq.  This methodology 
has brought a significant qualitative and quantitative improvement to transcriptome analysis, offering an 
unprecedented level of resolution able to detect genes expressed at low levels, splice isoforms and  novel 
exons/genes.[36] In addition, allele-specific expression, RNA editing and fusion transcripts represent some 
of the information that do not emerge from hybridization-based platforms and may be crucial in complex 
diseases.[37] 
 
1.3 EPIGENOMICS 
To date, studies on DNA methylation in IgAN are principally two (Supplementary Table 6). The first study 
showed that the gene expression of Cosmc, whose activity is closely related to aberrantly glycosylated IgA1, 
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could be regulated by DNA methylation in lymphocytes of children with IgAN.[38] Limitations of this study, 
in addition to the small sample size, are the lack of strong validation, functional assays  and DNA 
methylation analysis using a mixed cell population peripheral blood mononuclear cells (PBMCs). The second 
study showed that the two hypomethylated DNA regions contained the promoters for Dual Specificity 
Phosphatase 3 (DUSP3) and Tripartite Motif Containing 27 (TRIM27) and the most extensively 
hypermethylated region on chromosome 5 contained the Vault RNA 2-1 (VTRNA2-1) gene promoter, known 
as the precursor of miR-886. These aberrantly methylated DNA regions were found to induce a T helper cell 
imbalance towards the Th1 subtype. Even if the sample size is not very large, this study can be considerered 
confident due to the many validation experiments and functional assays. 
MicroRNAs (miRNAs) are another epigenetic component that can modulate gene expression in tissue and 
biological fluids. Three different genome-wide miRNA gene expression studies on IgAN patients'  blood cells 
have been performed (see Supplementary table 7).   A global miRNA expression study performed on IgAN 
patients PBMCsThe first study  led to the identification of two aberrantly expressed miRNAs ( let-7b and 
miR-148b) that regulate the gene expression of two  key enzymes involved in the sequential O-glycosylation 
process of the IgA1 molecule (GALNT2, C1GALT1).[39]  These results were validated biologically with 
transient transfection experiments and demonstrated that the abnormal miRNA-based regulatory 
mechanism influences the O-glycosylation process determining the aberrant glycosylation of IgA1, main 
characteristic of IgAN. [39, 40] These findings could be exploited for therapeutic use because the inhibition 
of these upregulated miRNAs could normalize the IgA1 O-glycosylation process. 
Recently, the miRNA expression profiling of B cells from IgAN patients [41] demonstrated an upregulation 
of miR-374b that is able to determine B cell proliferation and aberrant IgA1 glycosylation by targeting 
C1GALT1C1-Cosmc and Phosphatase and Tensin Homolog (PTEN); [41]  the latter has already been found 
aberrantly modulated in IgAN.[25] Anti-miR blockers could be exploited for new therapeutic approaches 
and are being tested in ex-vivo clinical studies on myocardial infarction,[42]  neoplasms[43] and in phase III 
clinical trials for hepatitis C virus infection.[41-44]  
While the majority of miRNAs are found within the cell, a handful of circulating miRNAs, released from 
blood cells, have also been detected in various body fluids.  In a multicenter international retrospective 
study, let-7b and miR-148b levels were measured in serum samples of Caucasian and Asian  IgAN patient 
sand their combined value was found as a significant predictor of the disease status,  showing  a good 
sensitivity and specificity and discriminating IgAN patients from other primary glomerulonephritides. [45].  
This combined biomarker seems to be a novel, specific and non-invasive indicator to test the probability of 
being affected by IgAN, mainly in patients’ relatives with persistent urinary abnormalities. 
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In the last years, several groups studied the role of miRNAs in kidney tissue. A cluster of miRNAs has been 
observed in the human kidney tissue with a different distribution in renal cortex and medulla of rat kidney. 
To date, few studies have been carried out on IgAN renal biopsies (see Supplementary table 8).  Abnormal 
miRNA expression patterns in renal biopsies correlated with glomerular sclerosis and interstitial fibrosis.  
Various miRNAs have been found to be involved in the progression of renal damage or in the pro-fibrotic 
processes in IgAN through E-cadherin and the epithelial to mesenchymal transition process. Recently, 
miRNAs have also been found to have a role in the activation of mesangial cells by secretory IgA (SIgA) from 
IgAN patients.[43] In conclusion, regarding the use of miRNAs as biomarkers in the blood and kidney, many 
studies have been conducted in retrospective cohorts but prospective studies are required to confirm their 
clinical utility and diagnostic value in asymptomatic individuals. In addition, several miRNAs have been 
identified as targets for the treatment but the use of miRNA modulators in pre-clinical settings is still 
missing.  
1.4 PROTEOMICS 
Urine is a biological fluid containing many cytokines that can be considered predictors of poor prognosis for 
the progression of the renal damage.[46, 47] Today, proteomics-based techniques, are promising 
approaches for uncovering new and more sensitive and relevant biomarkers that may be involved in the 
earlier phases of IgAN. Several studies have identified specific polypeptide patterns in patients’ urine, as 
reported in supplementary table 9 . Other proteins are able to differentiate IgAN from other diseases or 
distinguish specific proteomic profiles on the basis of disease severity or identify specific alterations during 
the progression of renal damage. Other urinary proteomics patterns distinguish progressor from non-
progressor IgAN patients. Some urinary  proteins are also predictive of inadequate response to ACEi.  
Data from the published articles do not evidence a common urinary pattern of polypeptides in the urine of 
IgAN patients probably due to different cohorts of patients included in the studies. However, some 
common proteins such as fragments of albumin, alfa1 antitrypsin, uromodulin, alfa1-microglobulin have 
been reported by many investigators.  
Limitations of the published studies are (i) different cohorts of IgAN patients included in the studies, (ii) 
different grades of renal damage; (iii) different techniques used for detecting urinary polypeptides; (iv) 
absence of validation in independent IgAN cohorts. Future studies should propend in the identification of a 
proteome based classifier containing specific peptides  able to discriminate IgAN patients with specific 
clinical patterns ( i.e. microscopic hematuria or patients with recurrent episodes of macroscopic hematuria)  
from healthy individuals and from other types of glomerulonephritis. The same classifier could be used as a 
disease outcome indicator or could be helpful in the evaluation of a therapeutic response. A urinary 
proteome based classifier CKD273 has successfully been identified in diabetic nephropathy and used in a 
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prospective randomised clinical trial.[48] This proteomic panel of 273 urinary peptides performed 
significantly better than albuminuria in predicting the early stages of CKD,[49], a similar approach is 
needed in IgAN.  
A recent development in the proteomic analysis is the new high-throughput Imaging Mass 
Spectrometry (IMS) technique for the identification, quantization and distribution of proteins, 
lipids and chemical metabolites at a picomol level in complex multicellular tissue,[50]  this 
procedure could be applied for the evaluation of  biopsy sections and help differentiate  IgAN sub-
phenotypes. Furthermore, IMS  has the power to discover specific 3D peptide profiles that are 
constitutively expressed in human cells and tissue types and in the future the IMS  integration with 
other OMICs such as genomics and transcriptomics will generate specific gene-transcipt-protein 
networks in health and disease. [51, 52] 
 
1.5 METABOLOMICS 
Metabolomics studies the individual metabolic profiles and their changes overtime due to physiological and 
pathological conditions (Supplementary Table 10). 1HNMR spectroscopy and pattern recognition analysis 
have been used by Del Coco et al  to detect minor alterations in the metabolomic  profile of urine from 
IgAN patients.[53] Data from NMR urine analysis evidenced altered values of specific metabolites 
(increased values of creatinine, TMAO, betaine and acetate, and decreased levels of hippurate, lactate and 
citrate). These results were confirmed in another study using the metabolomic urinary profiles of four 
primary glomerulonephrites where a specific urinary signature for IgAN patients was found.[54] Recently, 
Kalantari et al identified several urinary metabolite biomarkers  correlating with proteinuria and the most 
significant pathway associated with disease severity was the phenylalanine metabolic pathway.[55]  
These limited number of  studies demonstrate a specific metabolite signature in IgAN correlating with the 
severity of the renal damage. The presence of these metabolites in the urine reflects an altered metabolic 
pathway determined by an altered cell activity  highlighting new targets for specific therapy. However to 
confirm the validity of these results , data should be validated in larger independent and well phenotyped 
cohorts.  Moreover, the integrated analysis of genomics and urinary metabolomics could be considered a 
promising approach for uncovering novel gene to disease connections  via metabolic traits highlighting 
novel hypotheses about molecular mechanisms involved in the etiology of disease.[56] [57] 
1.6 CONCLUDING REMARKS 
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A summary of the results obtained from the omic studies including points of weaknesses and strengths are 
described in Table 1. 
Large-scale GWASs have been successfully applied in IgAN with extensively replicated results. To date 
GWASs  have identified highly relevant associated loci containing MHC regions, the complement system 
and genes involved in mucosal IgA production, innate immunity and inflammatory response.[11] Fine-
mapping studies are needed to uncover the causal genetic variants underlying the signals. Furthermore, 
identified rare/common variants underlying the IgAN phenotype must be validated with classical biological 
experimental approaches.  
The clinical approaches using FLOW-cytometry, Western blot, ELISA, Immunohistochemistry, transfection 
experiments, and others have been applied in transcriptomics/epigenomics/proteomics studies, but results 
require extensive replication. Moreover, metabolomics results must be replicated and applied on larger 
cohorts of well phenotyped IgAN patients.  
Results from different omics seem to be fragmented, but overlaps are evident when we focalize on the four 
hit pathogenic model (Table 2). High circulating levels of Gd-IgA1 (hit 1) are determined by a dysregulation 
in antigen handling and aberrancies in IgA1 production at mucosal sites.[58] All omics performed on PBLs 
show the involvement of altered innate and adaptive immunity. The altered response to an antigenic 
challenge clearly emerges during the gross hematuria episode[28]  with the up-regulation of interferon-
regulated genes involved in the degradation and processing of antigens  (TAP1, TAP2, PSMB8, PSMB9).[28] 
These genes are found in highly replicated GWAS loci[11] and have been validated with traditional 
experimental approaches by different authors.[27, 59] Another pathway that seems to be hyper-activated 
in this context is WNT–β-catenin, PI3K/Akt pathway mainly determined by the downregulation of the 
negative regulator PTEN and enhanced translocation of the effector molecule NF-κB.[27, 59] GWAS, rare 
genetic variants  and epigenetic studies support this hyperactivation with NF-κB translocation  occurring  
through  VAV3,[60] CARD9[61] and miR-374b,[41] the latter modulating  a B cell proliferation and aberrant 
IgA1 glycosylation. Interestingly, other miRNAs let-7b and miR-148b have also been demonstrated to 
regulate these pathways, let-7b directly regulates PTEN and miR-148b regulated both INVS and PTEN.[39] 
The same let-7b, miR-148b, miR-374b participate directly in the aberrant glycosylation process targeting  
respectively GALNT2, C1GALT1, C1GALT1C1-COSMC, important enzymes in the IgA1 glycosylation process.  
The Gd-IgA1 exposes N-acetylgalactosamine within IgA1 hinge-region and is  an epitope for the  anti-glycan 
response[62] that promotes the formation of circulating immune complexes (hit 2). This autoimmune 
phenotype could be regulated by MHC class II loci identified by GWAS ( HLA-DQA1, HLA-DQB1, HLA-DRB1, 
HLA-DP) and  triggered by the exposure to infectious or dietary antigens that have been aberrantly  
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processed. Furthermore, also the immunoproteasome (PSMB8, PSMB9, PSMB10, TAPBP) could be involved 
in this process as it is highly up-regulated  in a number of diseases including autoimmune diseases.  [63]  
The formation of circulating immune complexes and deposition (hit 3) may be elicited by the 
hyperactivation of PI3K/AKT pathway.  This pathway activates FcαRI (CD89) in monocytes.[64, 65] Then, 
circulating immune complexes aggregate this receptor inducing the shedding of the extracellular domain to 
form circulating IgA1–FcαRI complexes. Other receptors that are known to be involved in the deposition 
process (such as transglutaminase-2 , CD89, transferrin receptor, pIgR) have not been confirmed  by omic 
studies.  
Immuno-complex deposition induces mesangial cell proliferation, secretion of extracellular matrix 
chemokines and cytokines with an activation of the alternative complement pathway (hit 4). These 
pathways all seem to be evident in GWAS loci and  gene expression studies on kidney tissue. In particular, 
the activation of ITGAX-ITGAM, members of the complement system, encode for integrins αM and αX that 
combine with integrin β2 chain to form leukocyte-specific complement receptors 3 and 4, these receptors 
may augment glomerular inflammation. Toll-like receptor signalling, is also common to different omics and 
may be involved in the progression of the disease.  
 
1.7 FUTURE DIRECTIONS 
The use of molecular profiling technologies has identified different molecular signatures in IgAN associated 
with different phases of the disease and the progression of histologic lesions. The integration of data using 
an extensive computational support and statistical modelling is the key for connecting -omic data-sets with 
the clinical data[66] and for decoding the pathophysiological disease processes; it is which is necessary for 
an accurate and precise diagnosis and a more targeted therapy (Figure 1). Future omics studies should be 
applied on well phenotyped IgAN patients with extensive clinical data and MEST-C classification of renal 
damage. Common and rare gene variants located in the GWAS loci, PBMC gene expression data, molecular 
signature of renal lesions, clinical data (serum levels of aberrantly glycosylated  IgA1, miRNAs, eGFR and 
proteinuria, morphologic pictures) urinary polypeptides and metabolites should all be integrated for the 
identification of diagnostic biomarkers in IgAN and  risk prediction score.  The integrative analyses may be 
facilitated by the use of online resources like Nephroseq (https://www.nephroseq.org/resource/login.html) 
and KUPKB(kidney and urinary pathway knowledge base http://www.kupkb.org ) and other tools based on 
the ‘in silico’ nanodissection (http://nano.princeton.edu).   
To date high-throughput omics analyses are in progress; different issues have to be taken into 
consideration to discuss a concrete methodology for personalized health care starting from OMICs 
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data.[67] From a technical point of view, sample acquisition and data analysis should also be standardized 
and results need to be validated on different platforms in large cohorts of patients. Furthermore, the study 
biological component systems via the computational and mathematical modeling of complex biological 
systems,[68]  is the missing  link between OMICS and precision medicine in IgAN. This methodology is  
crucial to provide insights into new pathways and networks between OMICS to drive innovation through 
biology-based computational analysis that can detect aberrant networks at the onset of the disease and to 
enable patient stratification on the basis of their individual genetic and molecular profiles.[69]  The shift 
from the traditional ‘trial-and-error’ approach to precision medicine is possible if systems biology and 
multidisciplinary approaches  are undertaken as occurred in other diseases.[70]  
In conclusion, the integration of data results from and results from multi-level, high-dimensional data-sets 
is the next step for a better understanding of molecular networks and provides a unique resource for 
identifying new drug targetssystems pharmacology. Ultimately this methodology will lead to the 
identification of new molecular targets and personalized therapeutic approaches in different subsets of 
IgAN patients thus promoting  precision nephrology. 
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FIGURE 
Figure 1. Integrative analysis of clinical findings and omics data for a better molecular understanding of IgA 
Nephropathy leading towards precision nephrology and improvement in disease management 
(personalized therapy). RCTs: Randomized Controlled Trials; eGFR: Estimated Glomerular Filtration rate; 
SNPs: Single Nucleotide Polymorphisms; miRNAs: microRNA 
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Table 1.  Overview of Omics studies in IgA Nephropathy 
OMICS 
INPUT 
MATERIAL 
TISSUE 
ORIGIN 
STUDIES 
No. 
RESULTS WEAKNESSES STRENGTHS INVOLVED GENES/PATHWAYS 
GENOMICS 
DNA WB 5 51 CVs 
no validation with 
classical biological 
experimental 
approaches 
-large sample size 
 
-13 replicated CVs in 
Asian and European 
populations 
HLA-DRB1, HLA-DQA, HLA-DQB, CFHC,FHR3, CFHR1, 
CFHR4, CFHR2, CFHR5,TAP1,TAP2, PSMB8, PSMB9,VAV3. 
HORMAD2, MTMR3, LIF, OSM,HLA-DR,TNFSF13, MPDU1, 
EIF4A1.CD68,TP53, SOX15,ITGAM-ITGAX, HLA-DP, HLA-A, 
HLA-DQA/B,DEFAACCS,KLF10/ODF1,CARD9,HLA-DQ, 
ST6GAL1,HLA-DPB1,HLA-DPA2 
 
DNA WB 4 CNVs 
no validation with 
classical biological 
experimental 
approaches 
-CFH and Defensin loci 
have been replicated 
 
-  CNV real-time PCR 
assay validation for 
GALNT13, COL11A2, TLR9 
and  validation with 
classical biological 
experimental approaches 
and replication in Greek 
population 
CFHR3, CFHR1, HLA-DQB1, GALNT13, COL11A2, TLR9, 
DEFA3 
DNA WB 3 31 RVs 
RVs causality 
validation is missing 
RVs within previously 
validated aberrant 
networks 
MAPK/ERK pathway, PI3K/AKT pathway 
TRANSCRIPTOMICS 
RNA PBL 3 
470 
Dysregulated 
Genes 
-Results have not 
been replicated 
-small sample size 
validated with classical 
biological experimental 
approaches 
WNT–β-catenin and PI3K/Akt pathway (INVS , PTEN), 
Enhanced proliferation of PBMCs. 
Innate immunity activation  PSMB8, PSMB9 and  TAPBP  
 
RNA 
Blood 
CD14+ 
cells 
1 
710 
differently 
expressed 
genes 
-Results have not 
been replicated 
-small sample size 
validated with classical 
biological experimental 
approaches 
TNF, CD83, NDUFS3 and  TNFRSF1A  
RNA KIDNEY 4 
140 
differently 
expressed 
genes 
-Results have not 
been replicated 
-small sample size 
Some validated with 
classical biological 
experimental approaches 
innate immune response, classical complement pathway 
activation and matrix turnover.  Role of pattern 
recognition receptors in recognition of Bacteria and 
Viruses, Leukocyte extravasation signalling, TREM 
Signaling-ITGAX, NF-kB activation by viruses, Toll-like 
receptor Signaling, Cell cycle: G2/M DNA damage 
checkpoint regulation, IL-8 signaling, Production of nitric 
oxide and reactive oxygen species in macrophages 
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Abbreviations: CNVs: Copy number variations; CVs: common variants; PBL: peripheral blood leukocytes; PBMCs: Peripheral Blood Mononuclear Cells; RVs: rare variants; 
WB: whole blood; 
*In bold genes or pathways observed in more than one study. 
EPIGENOMICS 
DNA 
Blood 
CD4+CELL
S 
1 
Aberrantly 
metylated 
genes: DUSP3 
, TRIM27, 
VTRNA2-1,  
-Results have not 
been replicated 
-small sample size 
validated with classical 
biological experimental 
approaches 
T helper cell imbalance towards the Th1 subtype  
DNA PBMCs 1 
Aberrantly 
metylated 
genes: 
COSMC 
-Results have not 
been replicated 
-small sample size 
-results obtained 
from an  
heterogeneous cell 
population 
validated with classical 
biological experimental 
approaches 
COSMC metylation involved in aberrant glycosylation of 
IgA1 
Total RNA 
including 
miRNA 
PBMCs/SE
RUM 
2 
37 
dysregulated  
miRNAs 
-small sample size 
validated with classical 
biological experimental 
approaches 
replicated CVs in Asian 
and European 
populations 
 
-miRNAs involved in aberrant glycosylation of IgA1 
-let-7d directly regulates PTEN and miR-148b regulated 
both INVS and PTEN, 
Total RNA 
including 
miRNA 
CIRCULATI
NG CELLS 
1 
1 upregulated 
miRNA 
-small sample size 
validated with classical 
biological experimental 
approaches 
 
B cell proliferation by targeting PTEN 
miRNAs involved in aberrant glycosylation of IgA1 
targeting COSMC in B cells of IgAN. 
Total RNA 
including 
miRNA 
 
KIDNEY 6 14 
-small sample size 
-no validation with 
classical biological 
experimental 
approaches 
 
Abnormal miRNA expression patterns correlated with 
glomerular sclerosis and interstitial fibrosis and with 
progression of renal damage involving complement 
pathway( ITGAM-ITGAX) 
PROTEOMICS PROTEINS URINE 14 245 
-small sample size 
 
3 studies have been 
performed validations in 
independent cohorts 
Altered albumin, alfa1 antitrypsin, uromodulin, alfa1-
microglobulin,kininogen 
METABOLOMICS 
META 
BOLITES 
URINE 3  
-small sample size 
- no validation with 
classical biological 
experimental 
approaches 
 
 
Increased values of creatinine, TMAO, betaine and 
acetate, and decreased levels of hippurate, lactate and 
citrate 
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Table 2 Omics studies in the context of the four hit pathogenic model  
HIT PHASE PROCESS 
MOLECULAR 
PROCESSES 
INVOLVED 
OMICS CONTRIBUTIONS RELATED OMICS PATHOLOGICAL PROCESSES 
1 
High circulating levels of 
galactose-deficient IgA1 
(Gd-IgA1) 
Dysregulation of IgA1 
production at 
mucosal surfaces 
alterations in 
posttranslational 
modification of O-
glycans within IgA1-
producing cells. 
common genetic variants 
HORMAD2, LIF, OSM, DEFA, TNFSF13 genes appear to modulate mucosal immunity and production of 
IgA1. VAV3 essential for adaptive immune function and NF-κB activation in B-cells, a process that 
stimulates IgA production. ITGAM and ITGAX are involved in in intestinal inflammation and  IgA 
production. CARD9 activates NF-κB, which is responsible for both innate and adaptive immunity.  
TAP1,TAP2, PSMB8, PSMB9 are involved in the antigen presentation pathway. MHC class II alleles loci( 
HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DP) may participate in the regulation of intestinal inflammation 
and IgA production. 
rare genetic variants 
- Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single 
immune-related network where WNT–βcatenin, PI3K/Akt pathway and interferon signalling involve  both  
innate and adaptive immunity 
gene expression studies 
 
-Hyperactivation of WNT–β-catenin and PI3K/Akt pathways (down regulation of INVS and PTEN) leads to 
a defect in antigen handling and to abnormal systemic responses to mucosally encountered antigens. 
-Defect in antigen handling in PBMCs has been demonstrated during the macroscopic haematuria with a 
specific up-regulation of the immunoproteasome pathway (PSMB8, PSMB9, PSMB10 , TAPBP ) 
miRNA & metilation studies 
-miRNA let-7b and miR-148b modulate two enzymes involved in the sequential O-glycosylation process 
of the IgA1 molecule. Abnormal miRNA-based regulatory mechanism influence the O-glycosylation 
process determining the aberrant glycosylation of IgA1. Furthermore, let-7d directly regulates PTEN and 
miR-148b regulates both INVS and PTEN,- 
-Upregulation of miR-374b promotes B cell proliferation and aberrant IgA1 glycosylation by targeting 
Cosmc and PTEN 
-The gene expression of Cosmc, whose activity is closely related to Gd-IgA1, is regulated by DNA 
methylation in lymphocytes 
- Aberrantly methylated regions in CD4+ T-cells of IgAN patients led to the altered expression of genes 
involved in TCR signal transduction and in the reduced TCR signal strength explaining  the T-helper cell 
imbalance towards the Th1 subtype. 
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2 
Production of anti-Gd-
IgA1 autoantibodies of 
IgG and/or IgA isotype 
High Gd-IgA1 elicits 
an autoimmune 
response, resulting in 
generation of anti-
glycan antibodies that 
recognize N-
acetylgalactosamine 
epitopes on Gd-IgA1 
common genetic variants 
Anti-glycan response may be triggered by the exposure to infectious or dietary antigens that have been 
aberrantly  processed by genetically predisposing MHC class II allele loci: HLA-DQA1, HLA-DQB1, HLA-
DRB1, HLA-DP having  a role in autoimmunity 
gene expression studies 
Defect in antigen handling in PBMCs with an up-regulation of interferon signalling and 
immunoproteasome pathway (PSMB8, PSMB9, PSMB10, TAPBP) has been demonstrated in IgAN 
patients. These pathways seem to be upregulated in autoimmune diseases 
3 
Formation of circulating 
IgA1–IgG and IgA1–IgA1 
immune complexes and 
deposition 
Immune complexes 
activate alternative 
complement pathway 
common genetic variants ITGAM is essential for interactions between CD89 and secretory IgA 
gene expression studies 
-Hyperactivation of PI3K pathway in monocytes activates FcαRI and circulating immune complexes  
aggregate this receptor.  This interaction induces shedding of the extracellular domain to form circulating 
IgA1–FcαRI complexes that could have a pathogenic role in IgAN. 
- Gene expression studies on kidney tissue have evidenced ITGAM 
4 
Local activation of 
inflammatory pathways 
and the complement 
system 
local inflammation,  
mesangial cell 
proliferation,  
secretion pro-
inflammatory 
cytokines 
leading to the 
interstitial infiltration 
of inflammatory cells 
and  promoting 
glomerular and 
tubulointerstitial 
fibrosis 
common genetic variants 
- Glomerular inflammation is enhanced by the complement system - lectin or the alternative pathway ( 
CFHR3,1-del,  CFHR1 and CFHR3) 
- ITGAM and ITGAX encode integrins that combine to form leukocyte specific complement receptor CR3 
and CR4. These may be involved in glomerular inflammation. 
gene expression studies 
 
-Various gene expression studies conducted on kidney tissue show the involvement of relevant signalling 
pathways: Activation Complement system (ITGAX-ITGAM, C1QA, C1QB); Toll-like receptor Signalling;  NF-
kB pathway; IL-8 signalling; Production of nitric oxide and reactive oxygen species in macrophages;   
-Kidney production of cytokines (mainly IL6) promotes mesangial cell proliferation  
miRNA & metilation studies -TLR9 CNV  contributes to the deterioration of the renal function 
Proteomics 
-Low levels of UMOD peptides cause progression of renal damage 
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Summary 
IgA Nephropathy (IgAN) is the most common worldwide primary glomerulonephritis with a strong 
autoimmune component . The disease shows variability in both clinical phenotypes and endpoints, and can 
be potentially subdivided into more homogenous subtypes through the identification of specific molecular 
biomarkers. This review focuses on the role of -omics in driving the identification of potential molecular 
subtypes of the disease through the integration of multi-level data from genomics, transcriptomics, 
epigenomics, proteomics and metabolomics. First, the identification of molecular biomarkers, including 
mapping of the full spectrum of common and rare IgAN risk alleles, could permit a more precise 
stratification of IgAN patients. Second, the analysis of transcriptomic patterns and their modulation by 
epigenetic factors like miRNAs have the potential to increase our understanding in the pathogenic 
mechanisms of the disease. Third, the specificity of urinary proteomic and metabolomic signatures and the 
understanding of their functional relevance may contribute to the development of new non-invasive 
biomarkers for a better molecular characterization of the renal damage and its follow-up. All these 
approaches can give information for targeted therapeutic decisions and will support novel clinical decision 
making. In conclusion, we offer a framework of omic studies and outline barriers and potential solutions 
that should be used for improving the diagnosis and treatment of the disease. The ongoing decade is 
exploiting novel high-throughput molecular technologies and computational analyses for improving the 
diagnosis (precision nephrology) and treatment (personalised therapy) of the IgAN subtypes. 
 
 Key words  
IgA nephropathy, genomics, epigenomics, transcriptomics, proteomics, metabolomics,  
Running title :Omics in IgA Nephropathy 
WORD COUNT: 3807 
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Introduction  
IgA Nephropathy (IgAN) is the most common primary glomerulonephritis worldwide [1, 2] that develops 
mainly  in the 2
nd
 and 3
rd
 decade of life and 40% of IgAN cases reach end-stage kidney disease (ESKD) after 
20 years from the biopsy-proven diagnosis implying a great socio-economical burden.[3, 4] 
  
In this review, 
we describe the results of omics studies carried out in IgAN patients. We move from genomic studies 
focusing on common and rare variants linked to the disease, to transcriptomics carried out on circulating 
immune cells and kidney biopsy specimens and then to epigenomics, proteomics and metabolomics . 
Finally, we suggest an integrative approach for developing biological networks and identify potential 
diagnostic biomarkers for Precision Nephrology and Personalized Therapy. 
 
1.1 GENOMICS 
Two main genome wide genetic approach s have been used in the study of this complex disease: Genome 
Wide Association Studies (GWAS) and Next Generation Sequencing (NGS).  
1.1.1 Common Variants 
The GWAS conducted on IgAN have identified several common variants that clearly show a strong 
participation of the Human Leukocyte Antigen (HLA) system, genes involved in innate immunity, and other 
loci summarized in Supplementary Table 1. Seven Single-Nucleotide Polymorphisms (SNPs) identified 
through GWAS were used for constructing a genetic risk score, which explained 4.7% of overall IgAN risk.[5] 
This score was integrated with other 8 recently associated SNPs, but it cumulatively explains only 5.37% of 
disease risk (http://www.columbiamedicine.org/divisions/gharavi/calc_genetic.php). [6]  In summary, IgAN 
risk loci identified through GWAS i) are common to other inflammatory and immune-mediated diseases, ii) 
explain a proportion of the disease risk worldwide, iii) contribute to the geographic variation in disease 
prevalence, iv) confirm the polygenic and multiple-susceptibility-gene nature of IgAN. Future studies are 
needed to evaluate if these GWAS signals are effectively generated by causative common variants or due to 
rare variants in linkage disequilibrium with the common ones. Direct sequencing of the associated regions 
may lead to a finer mapping of these disease-related loci, as seen for example in chronic obstructive 
pulmonary disease. [7] 
 Very recently two quantitative GWAS have identified two loci, in core 1, β1-3-galactosyltransferase-1 
(C1GALT1) and C1GALT1 Specific Chaperone 1 (C1GALT1C1-cosmc)[8, 9] providing novel insights into the 
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genetic regulation of O-glycosylation and providing evidence that also common genetic variations can 
influence O-glycosylation. 
Copy Number Variants (CNVs) in IgAN have been reported in complement Factor H Related proteins(CFHR1, 
CFHR3) [10, 11]  and have been associated with decreased IgAN risk (supplementary Table 2). CNVs were 
also found enriched in the linked 17q12-22 locus [12, 13] and in the Toll Like Receptor 9 (TLR9) gene where 
its potential role in disease progression was confirmed.[13] A lower copy number of three variants within 
the defensin highly variable locus correlated with renal dysfunction, increased serum IgA1 and Gd-IgA1.[14, 
15] 
1.1.2 Rare variants 
Rare variants, usually found in the frequency range between 0.1% and 1%, are more likely to have a 
stronger effect in complex diseases compared to common variants. Three Whole Exome Sequencing (WES) 
studies have been performed on IgAN (Supplementary Table 3). The first study evidenced seven common 
co-segregating deleterious variants within four genes (CARD8, DEFA4; MYCT1, ZNF543).[16] The second 
WES study performed on two affected individuals and an unaffected familial control from a large Sicilian 
family with multiple affected individuals, identified a novel missense variant in the Sprouty RTK Signaling 
Antagonist 2 (SPRY2) gene that segregated in all IgAN affected individuals.[17] Functional analysis of the 
variant in B lymphoblastoid cell lines from affected members linked the SPRY2 mutation showed the 
inhibition of the MAPK/ERK pathway. Recently, a combined linkage analysis and exome sequencing 
methodology has been successfully applied for pinpointing specific causative variants involved in familial 
goiter.[18] A similar procedure has been carried out by Cox et al. In the last IgAN study and their results 
support  a polygenic and a multiple-susceptibility-gene model for familial IgAN.[19] Evident connections 
with previous gene expression studies were found, but further studies are needed to understand whether 
these variants can effectively disrupt gene function and validate their causality in contributing to IgAN 
phenotype. Furthermore, these studies must be replicated in other independent cohorts of IgAN patients 
to confirm the validity of the results. 
To date several efforts have been made to identify susceptibility variants, but NGS data for the 
identification of rare variants within IgAN GWAS areas has never been done. This strategy has been recently 
applied in the study of age-related macular degeneration in which rare causative coding variants were 
pinpointed within known associated genetic loci and could represent an innovative and promising approach 
for IgAN.[20] Association testing deployed in parallel or in combination to familial linkage could represent  
another innovative strategy for the identification and characterization of a full range of disease-
susceptibility variants as seen in hearing impairment  and cardiomyopathy .[21-24]  
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1.2 TRANSCRIPTOMICS 
Transcriptome is considered the gene signature leading to a phenotype that is possibly influenced by 
genetic determinants. Specific gene expression patterns have been found in IgAN patients' blood cells. 
(Supplementary Table 4). An aberrant modulation of genes belonging to the WNT-β-catenin and PI3K/AKT 
pathways was found in peripheral blood leukocytes (PBL) IgAN patients.[25] Monocytes were principally 
involved in the altered WNT signaling pathway and an expansion of the non-classical CD16+ monocyte 
subset characterized by an enhanced apoptotic potential was demonstrated.[26] Moreover, 
transcriptomics was used to analyze gross hematuria episodes in concomitance to mucosal infections,  an 
important time point for IgAN.[27, 28]
 
 Differently regulated genes during the gross hematuria episode 
were principally involved in interferon signaling and antigen presentation.[28]
 
This network showed an up-
regulation of genes involved in the immune-proteasome pathway and based on a series of additional 
experimental approaches, C-X3-C Motif Chemokine Receptor 1 (CX3CR1) and its ligand fractalkine were 
found to promote macroscopic hematuria in IgAN patients. An important limitation of all these 
experimental approaches is that gene expression data have not been integrated with genome wide 
genotype data. This integration could be useful for the identification of expression quantitative trait loci 
(eQTL) giving a direct genetic explanation of aberrant gene expression data, useful for translational 
medicine.[29]  
Most transcriptomic findings have been obtained from complex starting material i.e whole blood, which is 
made up of different cell lineages. Future studies should propend towards the use of cell sorting 
technologies for analyzing the transcriptomic profile of specific cell populations or single cell analysis may 
give novel insights into health and disease status.[30]  These novel technological approaches may help to 
obtain cell-lineage specific expression data from IgA1 secreting cells, giving important insights into the 
pathogenic  mechanisms involved in the disease.   
The renal damage in IgAN is caused by mesangial deposition of polymeric IgA1 and or IgA1-IgG immune 
complexes at glomerular level leading to oversynthesis of extracellular matrix (ECM). Since alterations in 
mRNA levels could precede the histological damage, transcriptomics in kidney tissue might identify gene 
expression profiles involved in the development and progression of renal damage.  
Investigators focused their attention on the gene expression of isolated glomeruli or tubulointerstitial 
tissue from IgAN patients' kidney biopsies. They observed an increased expression of some proteoglycans 
directly involved in renal damage and suggested their potential role as prognostic biomarkers and 
highlighted an 11 transcript proteinuria signature in the tubulo-interstitial compartement.[31, 32] 
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Differently expressed genes in microdissected glomeruli with endocapillary proliferation were involved in 
innate immune response, classical complement pathway activation and matrix turnover. Interestingly, the 
in-silico study demonstrated that the aberrantly expressed genes characterizing endocapillary proliferation 
were responsive to the combined corticosteroid-resveratol therapy.[33] A subsequent study demonstrated 
that altered expressed genes were responsive to some organic substances such as doxorubicin and 
thapsigargin[34] (see supplementary Table 5).  
Data from these studies indicate that (i) glomerular and tubulointerstitial gene expressions are 
independent; (ii) some genes involved in specific pathways are responsive to drugs.  Gene expression data 
from isolated glomeruli or tubules are not correlated to the extent of renal damage but it's a sterile 
description of up and down-regulated genes. Future studies should be performed on the entire tissue as 
whole since kidney disease involves all renal compartments globally and simultaneously. In particular, gene 
expression studies will need to be performed on well characterized kidney biopsy specimens that have 
been accurately  scored with the new reproducible MEST-C classification system.[35] In this way specific 
gene expression changes that characterize active renal lesions (E and C) that are more responsive to 
immunosuppressive therapy compared to chronic lesions (S and T) wiil be identified. Furthermore, 
differences in gene expression linked to the degree of histologic renal damage have yet to be evaluated. 
This information is important because glomerular lesions are always associated with tubulointerstitial 
damage during the progression of renal damage.  
The emerging transcriptomic methodology not deployed in the study of IgAN is RNAseq.  This methodology 
has brought a significant qualitative and quantitative improvement to transcriptome analysis, offering an 
unprecedented level of resolution able to detect genes expressed at low levels, splice isoforms and  novel 
exons/genes.[36] In addition, allele-specific expression, RNA editing and fusion transcripts represent some 
of the information that do not emerge from hybridization-based platforms and may be crucial in complex 
diseases.[37] 
 
1.3 EPIGENOMICS 
To date, studies on DNA methylation in IgAN are principally two (Supplementary Table 6). The first study 
showed that the gene expression of Cosmc, whose activity is closely related to aberrantly glycosylated IgA1, 
could be regulated by DNA methylation in lymphocytes of children with IgAN.[38] Limitations of this study, 
in addition to the small sample size, are the lack of strong validation, functional assays  and DNA 
methylation analysis using a mixed cell population peripheral blood mononuclear cells (PBMCs). The second 
study showed that the two hypomethylated DNA regions contained the promoters for Dual Specificity 
Page 29 of 45 Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
7 
 
Phosphatase 3 (DUSP3) and Tripartite Motif Containing 27 (TRIM27) and the most extensively 
hypermethylated region on chromosome 5 contained the Vault RNA 2-1 (VTRNA2-1) gene promoter, known 
as the precursor of miR-886. These aberrantly methylated DNA regions were found to induce a T helper cell 
imbalance towards the Th1 subtype. Even if the sample size is not very large, this study can be considerered 
confident due to the many validation experiments and functional assays. 
MicroRNAs (miRNAs) are another epigenetic component that can modulate gene expression in tissue and 
biological fluids. Three different genome-wide miRNA gene expression studies on IgAN patients'  blood cells 
have been performed (see Supplementary table 7).   The first study  led to the identification of two 
aberrantly expressed miRNAs ( let-7b and miR-148b) that regulate the gene expression of two  key enzymes 
involved in the sequential O-glycosylation process of the IgA1 molecule (GALNT2, C1GALT1).[39]  These 
results were validated biologically with transient transfection experiments and demonstrated that the 
abnormal miRNA-based regulatory mechanism influences the O-glycosylation process determining the 
aberrant glycosylation of IgA1, main characteristic of IgAN. [39, 40] These findings could be exploited for 
therapeutic use because the inhibition of these upregulated miRNAs could normalize the IgA1 O-
glycosylation process. 
Recently, the miRNA expression profiling of B cells from IgAN patients demonstrated an upregulation of 
miR-374b that is able to determine B cell proliferation and aberrant IgA1 glycosylation by targeting 
C1GALT1C1-Cosmc and Phosphatase and Tensin Homolog (PTEN); [41]  the latter has already been found 
aberrantly modulated in IgAN.[25] Anti-miR blockers could be exploited for new therapeutic approaches 
and are being tested in ex-vivo clinical studies on myocardial infarction, neoplasms and in phase III clinical 
trials for hepatitis C virus infection.[41-44]  
While the majority of miRNAs are found within the cell, a handful of circulating miRNAs, released from 
blood cells, have also been detected in various body fluids.  In a multicenter international retrospective 
study, let-7b and miR-148b levels were measured in serum samples of Caucasian and Asian  IgAN patient 
sand their combined value was found as a significant predictor of the disease status,  showing  a good 
sensitivity and specificity and discriminating IgAN patients from other primary glomerulonephritides. [45] 
This combined biomarker seems to be a novel, specific and non-invasive indicator to test the probability of 
being affected by IgAN, mainly in patients’ relatives with persistent urinary abnormalities. 
In the last years, several groups studied the role of miRNAs in kidney tissue. A cluster of miRNAs has been 
observed in the human kidney tissue with a different distribution in renal cortex and medulla of rat kidney. 
To date, few studies have been carried out on IgAN renal biopsies (see Supplementary table 8).  Abnormal 
miRNA expression patterns in renal biopsies correlated with glomerular sclerosis and interstitial fibrosis.
 
 
Various miRNAs have been found to be involved in the progression of renal damage
 
or in the pro-fibrotic 
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processes in IgAN through E-cadherin and the epithelial to mesenchymal transition process. Recently, 
miRNAs have also been found to have a role in the activation of mesangial cells by secretory IgA (SIgA) from 
IgAN patients.[43] In conclusion, regarding the use of miRNAs as biomarkers in the blood and kidney, many 
studies have been conducted in retrospective cohorts but prospective studies are required to confirm their 
clinical utility and diagnostic value in asymptomatic individuals. In addition, several miRNAs have been 
identified as targets for the treatment but the use of miRNA modulators in pre-clinical settings is still 
missing.  
1.4 PROTEOMICS 
Urine is a biological fluid containing many cytokines that can be considered predictors of poor prognosis for 
the progression of the renal damage.[46, 47]
 
Today, proteomics-based techniques, are promising 
approaches for uncovering new and more sensitive and relevant biomarkers that may be involved in the 
earlier phases of IgAN. Several studies have identified specific polypeptide patterns in patients’ urine, as 
reported in supplementary table 9 . Other proteins are able to differentiate IgAN from other diseases or 
distinguish specific proteomic profiles on the basis of disease severity or identify specific alterations during 
the progression of renal damage. Other urinary proteomics patterns distinguish progressor from non-
progressor IgAN patients. Some urinary  proteins are also predictive of inadequate response to ACEi.  
Data from the published articles do not evidence a common urinary pattern of polypeptides in the urine of 
IgAN patients probably due to different cohorts of patients included in the studies. However, some 
common proteins such as fragments of albumin, alfa1 antitrypsin, uromodulin, alfa1-microglobulin have 
been reported by many investigators.  
Limitations of the published studies are (i) different cohorts of IgAN patients included in the studies, (ii) 
different grades of renal damage; (iii) different techniques used for detecting urinary polypeptides; (iv) 
absence of validation in independent IgAN cohorts. Future studies should propend in the identification of a 
proteome based classifier containing specific peptides  able to discriminate IgAN patients with specific 
clinical patterns ( i.e. microscopic hematuria or patients with recurrent episodes of macroscopic hematuria)  
from healthy individuals and from other types of glomerulonephritis. The same classifier could be used as a 
disease outcome indicator or could be helpful in the evaluation of a therapeutic response. A urinary 
proteome based classifier CKD273 has successfully been identified in diabetic nephropathy and used in a 
prospective randomised clinical trial.[48] This proteomic panel of 273 urinary peptides performed 
significantly better than albuminuria in predicting the early stages of CKD,[49] a similar approach is 
needed in IgAN.  
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A recent development in the proteomic analysis is the new high-throughput Imaging Mass 
Spectrometry (IMS) technique for the identification, quantization and distribution of proteins, 
lipids and chemical metabolites at a picomol level in complex multicellular tissue,[50]  this 
procedure could be applied for the evaluation of  biopsy sections and help differentiate  IgAN sub-
phenotypes. Furthermore, IMS  has the power to discover specific 3D peptide profiles that are 
constitutively expressed in human cells and tissue types and in the future the IMS  integration with 
other OMICs such as genomics and transcriptomics will generate specific gene-transcipt-protein 
networks in health and disease. [51, 52] 
1.5 METABOLOMICS 
Metabolomics studies the individual metabolic profiles and their changes overtime due to physiological and 
pathological conditions (Supplementary Table 10). 
1
HNMR spectroscopy and pattern recognition analysis 
have been used by Del Coco et al  to detect minor alterations in the metabolomic  profile of urine from 
IgAN patients.[53] Data from NMR urine analysis evidenced altered values of specific metabolites 
(increased values of creatinine, TMAO, betaine and acetate, and decreased levels of hippurate, lactate and 
citrate). These results were confirmed in another study using the metabolomic urinary profiles of four 
primary glomerulonephrites where a specific urinary signature for IgAN patients was found.[54] Recently, 
Kalantari et al identified several urinary metabolite biomarkers  correlating with proteinuria and the most 
significant pathway associated with disease severity was the phenylalanine metabolic pathway.[55]  
These limited number of  studies demonstrate a specific metabolite signature in IgAN correlating with the 
severity of the renal damage. The presence of these metabolites in the urine reflects an altered metabolic 
pathway determined by an altered cell activity  highlighting new targets for specific therapy. However to 
confirm the validity of these results , data should be validated in larger independent and well phenotyped 
cohorts.  Moreover, the integrated analysis of genomics and urinary metabolomics could be considered a 
promising approach for uncovering novel gene to disease connections  via metabolic traits highlighting 
novel hypotheses about molecular mechanisms involved in the etiology of disease.[56] [57] 
1.6 CONCLUDING REMARKS 
A summary of the results obtained from the omic studies including points of weaknesses and strengths are 
described in Table 1. 
Large-scale GWASs have been successfully applied in IgAN with extensively replicated results. To date 
GWASs  have identified highly relevant associated loci containing MHC regions, the complement system 
and genes involved in mucosal IgA production, innate immunity and inflammatory response.[11] Fine-
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mapping studies are needed to uncover the causal genetic variants underlying the signals. Furthermore, 
identified rare/common variants underlying the IgAN phenotype must be validated with classical biological 
experimental approaches.  
The clinical approaches using FLOW-cytometry, Western blot, ELISA, Immunohistochemistry, transfection 
experiments, and others have been applied in transcriptomics/epigenomics/proteomics studies, but results 
require extensive replication. Moreover, metabolomics results must be replicated and applied on larger 
cohorts of well phenotyped IgAN patients.  
Results from different omics seem to be fragmented, but overlaps are evident when we focalize on the four 
hit pathogenic model (Table 2). High circulating levels of Gd-IgA1 (hit 1) are determined by a dysregulation 
in antigen handling and aberrancies in IgA1 production at mucosal sites.[58] All omics performed on PBLs 
show the involvement of altered innate and adaptive immunity. The altered response to an antigenic 
challenge clearly emerges during the gross hematuria episode with the up-regulation of interferon-
regulated genes involved in the degradation and processing of antigens  (TAP1, TAP2, PSMB8, PSMB9).[28] 
These genes are found in highly replicated GWAS loci[11] and have been validated with traditional 
experimental approaches by different authors.[27, 59] Another pathway that seems to be hyper-activated 
in this context is WNT–β-catenin, PI3K/Akt pathway mainly determined by the downregulation of the 
negative regulator PTEN and enhanced translocation of the effector molecule NF-κB.[27, 59] GWAS, rare 
genetic variants  and epigenetic studies support this hyperactivation with NF-κB translocation  occurring  
through  VAV3,[60] CARD9[61] and miR-374b,[41] the latter modulating  a B cell proliferation and aberrant 
IgA1 glycosylation. Interestingly, other miRNAs let-7b and miR-148b have also been demonstrated to 
regulate these pathways, let-7b directly regulates PTEN and miR-148b regulated both INVS and PTEN.[39] 
The same let-7b, miR-148b, miR-374b participate directly in the aberrant glycosylation process targeting  
respectively GALNT2, C1GALT1, C1GALT1C1-COSMC, important enzymes in the IgA1 glycosylation process.  
The Gd-IgA1 exposes N-acetylgalactosamine within IgA1 hinge-region and is  an epitope for the  anti-glycan 
response[62] that promotes the formation of circulating immune complexes (hit 2). This autoimmune 
phenotype could be regulated by MHC class II loci identified by GWAS ( HLA-DQA1, HLA-DQB1, HLA-DRB1, 
HLA-DP) and  triggered by the exposure to infectious or dietary antigens that have been aberrantly  
processed. Furthermore, also the immunoproteasome (PSMB8, PSMB9, PSMB10, TAPBP) could be involved 
in this process as it is highly up-regulated  in a number of diseases including autoimmune diseases. [63]  
The formation of circulating immune complexes and deposition (hit 3) may be elicited by the 
hyperactivation of PI3K/AKT pathway.  This pathway activates FcαRI (CD89) in monocytes.[64, 65] Then, 
circulating immune complexes aggregate this receptor inducing the shedding of the extracellular domain to 
form circulating IgA1–FcαRI complexes. Other receptors that are known to be involved in the deposition 
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process (such as transglutaminase-2 , CD89, transferrin receptor, pIgR) have not been confirmed  by omic 
studies.  
Immuno-complex deposition induces mesangial cell proliferation, secretion of extracellular matrix 
chemokines and cytokines with an activation of the alternative complement pathway (hit 4). These 
pathways all seem to be evident in GWAS loci and  gene expression studies on kidney tissue. In particular, 
the activation of ITGAX-ITGAM, members of the complement system, encode for integrins αM and αX that 
combine with integrin β2 chain to form leukocyte-specific complement receptors 3 and 4, these receptors 
may augment glomerular inflammation. Toll-like receptor signalling, is also common to different omics and 
may be involved in the progression of the disease.  
 
1.7 FUTURE DIRECTIONS 
The use of molecular profiling technologies has identified different molecular signatures in IgAN associated 
with different phases of the disease and the progression of histologic lesions. The integration of data using 
an extensive computational support and statistical modelling is the key for connecting omic data-sets with 
the clinical data[66] and for decoding the pathophysiological disease processes; it is necessary for an 
accurate and precise diagnosis and a more targeted therapy (Figure 1). Future omics studies should be 
applied on well phenotyped IgAN patients with extensive clinical data and MEST-C classification of renal 
damage. Common and rare gene variants located in the GWAS loci, PBMC gene expression data, molecular 
signature of renal lesions, clinical data (serum levels of aberrantly glycosylated  IgA1, miRNAs, eGFR and 
proteinuria, morphologic pictures) urinary polypeptides and metabolites should all be integrated for the 
identification of diagnostic biomarkers in IgAN and  risk prediction score.  The integrative analyses may be 
facilitated by the use of online resources like Nephroseq (https://www.nephroseq.org/resource/login.html) 
and KUPKB(kidney and urinary pathway knowledge base http://www.kupkb.org ) and other tools based on 
the ‘in silico’ nanodissection (http://nano.princeton.edu).  To date high-throughput omics analyses are in 
progress; different issues have to be taken into consideration to discuss a concrete methodology for 
personalized health care starting from OMICs data.[67] From a technical point of view, sample acquisition 
and data analysis should also be standardized and results need to be validated on different platforms in 
large cohorts of patients. Furthermore, the study biological component systems via the computational and 
mathematical modeling of complex biological systems,[68]  is the missing  link between OMICS and 
precision medicine in IgAN. This methodology is  crucial to provide insights into new pathways and 
networks between OMICS to drive innovation through biology-based computational analysis that can 
detect aberrant networks at the onset of the disease and to enable patient stratification on the basis of 
their individual genetic and molecular profiles.[69]  The shift from the traditional ‘trial-and-error’ approach 
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to precision medicine is possible if systems biology and multidisciplinary approaches  are undertaken as 
occurred in other diseases.[70]  
In conclusion, the integration of results from multi-level, high-dimensional data-sets is the next step for a 
better understanding of molecular networks and provides a unique resource for identifying new drug 
targets. Ultimately this methodology will lead to personalized therapeutic approaches in different subsets 
of IgAN patients thus promoting  precision nephrology. 
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FIGURE 
Figure 1. Integrative analysis of clinical findings and omics data for a better molecular understanding of IgA 
Nephropathy leading towards precision nephrology and improvement in disease management 
(personalized therapy). RCTs: Randomized Controlled Trials; eGFR: Estimated Glomerular Filtration rate; 
SNPs: Single Nucleotide Polymorphisms; miRNAs: microRNA 
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Table 1.  Overview of Omics studies in IgA Nephropathy 
OMICS 
INPUT 
MATERIAL 
TISSUE 
ORIGIN 
STUDIES 
No. 
RESULTS WEAKNESSES STRENGTHS INVOLVED GENES/PATHWAYS 
GENOMICS 
DNA WB 5 51 CVs 
no validation with 
classical biological 
experimental 
approaches 
-large sample size 
 
-13 replicated CVs in 
Asian and European 
populations 
HLA-DRB1, HLA-DQA, HLA-DQB, CFHC,FHR3, CFHR1, 
CFHR4, CFHR2, CFHR5,TAP1,TAP2, PSMB8, PSMB9,VAV3. 
HORMAD2, MTMR3, LIF, OSM,HLA-DR,TNFSF13, MPDU1, 
EIF4A1.CD68,TP53, SOX15,ITGAM-ITGAX, HLA-DP, HLA-A, 
HLA-DQA/B,DEFAACCS,KLF10/ODF1,CARD9,HLA-DQ, 
ST6GAL1,HLA-DPB1,HLA-DPA2 
 
DNA WB 4 CNVs 
no validation with 
classical biological 
experimental 
approaches 
-CFH and Defensin loci 
have been replicated 
 
-  CNV real-time PCR 
assay validation for 
GALNT13, COL11A2, TLR9 
and  validation with 
classical biological 
experimental approaches 
and replication in Greek 
population 
CFHR3, CFHR1, HLA-DQB1, GALNT13, COL11A2, TLR9, 
DEFA3 
DNA WB 3 31 RVs 
RVs causality 
validation is missing 
RVs within previously 
validated aberrant 
networks 
MAPK/ERK pathway, PI3K/AKT pathway 
TRANSCRIPTOMICS 
RNA PBL 3 
470 
Dysregulated 
Genes 
-Results have not 
been replicated 
-small sample size 
validated with classical 
biological experimental 
approaches 
WNT–β-catenin and PI3K/Akt pathway (INVS , PTEN), 
Enhanced proliferation of PBMCs. 
Innate immunity activation  PSMB8, PSMB9 and  TAPBP  
 
RNA 
Blood 
CD14+ 
cells 
1 
710 
differently 
expressed 
genes 
-Results have not 
been replicated 
-small sample size 
validated with classical 
biological experimental 
approaches 
TNF, CD83, NDUFS3 and  TNFRSF1A  
RNA KIDNEY 4 
140 
differently 
expressed 
genes 
-Results have not 
been replicated 
-small sample size 
Some validated with 
classical biological 
experimental approaches 
innate immune response, classical complement pathway 
activation and matrix turnover.  Role of pattern 
recognition receptors in recognition of Bacteria and 
Viruses, Leukocyte extravasation signalling, TREM 
Signaling-ITGAX, NF-kB activation by viruses, Toll-like 
receptor Signaling, Cell cycle: G2/M DNA damage 
checkpoint regulation, IL-8 signaling, Production of nitric 
oxide and reactive oxygen species in macrophages 
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Abbreviations: CNVs: Copy number variations; CVs: common variants; PBL: peripheral blood leukocytes; PBMCs: Peripheral Blood Mononuclear Cells; RVs: rare variants; 
WB: whole blood; 
*In bold genes or pathways observed in more than one study. 
EPIGENOMICS 
DNA 
Blood 
CD4+CELL
S 
1 
Aberrantly 
metylated 
genes: DUSP3 
, TRIM27, 
VTRNA2-1,  
-Results have not 
been replicated 
-small sample size 
validated with classical 
biological experimental 
approaches 
T helper cell imbalance towards the Th1 subtype  
DNA PBMCs 1 
Aberrantly 
metylated 
genes: 
COSMC 
-Results have not 
been replicated 
-small sample size 
-results obtained 
from an  
heterogeneous cell 
population 
validated with classical 
biological experimental 
approaches 
COSMC metylation involved in aberrant glycosylation of 
IgA1 
Total RNA 
including 
miRNA 
PBMCs/SE
RUM 
2 
37 
dysregulated  
miRNAs 
-small sample size 
validated with classical 
biological experimental 
approaches 
replicated CVs in Asian 
and European 
populations 
 
-miRNAs involved in aberrant glycosylation of IgA1 
-let-7d directly regulates PTEN and miR-148b regulated 
both INVS and PTEN, 
Total RNA 
including 
miRNA 
CIRCULATI
NG CELLS 
1 
1 upregulated 
miRNA 
-small sample size 
validated with classical 
biological experimental 
approaches 
 
B cell proliferation by targeting PTEN 
miRNAs involved in aberrant glycosylation of IgA1 
targeting COSMC in B cells of IgAN. 
Total RNA 
including 
miRNA 
 
KIDNEY 6 14 
-small sample size 
-no validation with 
classical biological 
experimental 
approaches 
 
Abnormal miRNA expression patterns correlated with 
glomerular sclerosis and interstitial fibrosis and with 
progression of renal damage involving complement 
pathway( ITGAM-ITGAX) 
PROTEOMICS PROTEINS URINE 14 245 
-small sample size 
 
3 studies have been 
performed validations in 
independent cohorts 
Altered albumin, alfa1 antitrypsin, uromodulin, alfa1-
microglobulin,kininogen 
METABOLOMICS 
META 
BOLITES 
URINE 3  
-small sample size 
- no validation with 
classical biological 
experimental 
approaches 
 
 
Increased values of creatinine, TMAO, betaine and 
acetate, and decreased levels of hippurate, lactate and 
citrate 
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Table 2 Omics studies in the context of the four hit pathogenic model  
HIT PHASE PROCESS 
MOLECULAR 
PROCESSES 
INVOLVED 
OMICS CONTRIBUTIONS RELATED OMICS PATHOLOGICAL PROCESSES 
1 
High circulating levels of 
galactose-deficient IgA1 
(Gd-IgA1) 
Dysregulation of IgA1 
production at 
mucosal surfaces 
alterations in 
posttranslational 
modification of O-
glycans within IgA1-
producing cells. 
common genetic variants 
HORMAD2, LIF, OSM, DEFA, TNFSF13 genes appear to modulate mucosal immunity and production of 
IgA1. VAV3 essential for adaptive immune function and NF-κB activation in B-cells, a process that 
stimulates IgA production. ITGAM and ITGAX are involved in in intestinal inflammation and  IgA 
production. CARD9 activates NF-κB, which is responsible for both innate and adaptive immunity.  
TAP1,TAP2, PSMB8, PSMB9 are involved in the antigen presentation pathway. MHC class II alleles loci( 
HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DP) may participate in the regulation of intestinal inflammation 
and IgA production. 
rare genetic variants 
- Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single 
immune-related network where WNT–βcatenin, PI3K/Akt pathway and interferon signalling involve  both  
innate and adaptive immunity 
gene expression studies 
 
-Hyperactivation of WNT–β-catenin and PI3K/Akt pathways (down regulation of INVS and PTEN) leads to 
a defect in antigen handling and to abnormal systemic responses to mucosally encountered antigens. 
-Defect in antigen handling in PBMCs has been demonstrated during the macroscopic haematuria with a 
specific up-regulation of the immunoproteasome pathway (PSMB8, PSMB9, PSMB10 , TAPBP ) 
miRNA & metilation studies 
-miRNA let-7b and miR-148b modulate two enzymes involved in the sequential O-glycosylation process 
of the IgA1 molecule. Abnormal miRNA-based regulatory mechanism influence the O-glycosylation 
process determining the aberrant glycosylation of IgA1. Furthermore, let-7d directly regulates PTEN and 
miR-148b regulates both INVS and PTEN,- 
-Upregulation of miR-374b promotes B cell proliferation and aberrant IgA1 glycosylation by targeting 
Cosmc and PTEN 
-The gene expression of Cosmc, whose activity is closely related to Gd-IgA1, is regulated by DNA 
methylation in lymphocytes 
- Aberrantly methylated regions in CD4+ T-cells of IgAN patients led to the altered expression of genes 
involved in TCR signal transduction and in the reduced TCR signal strength explaining  the T-helper cell 
imbalance towards the Th1 subtype. 
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2 
Production of anti-Gd-
IgA1 autoantibodies of 
IgG and/or IgA isotype 
High Gd-IgA1 elicits 
an autoimmune 
response, resulting in 
generation of anti-
glycan antibodies that 
recognize N-
acetylgalactosamine 
epitopes on Gd-IgA1 
common genetic variants 
Anti-glycan response may be triggered by the exposure to infectious or dietary antigens that have been 
aberrantly  processed by genetically predisposing MHC class II allele loci: HLA-DQA1, HLA-DQB1, HLA-
DRB1, HLA-DP having  a role in autoimmunity 
gene expression studies 
Defect in antigen handling in PBMCs with an up-regulation of interferon signalling and 
immunoproteasome pathway (PSMB8, PSMB9, PSMB10, TAPBP) has been demonstrated in IgAN 
patients. These pathways seem to be upregulated in autoimmune diseases 
3 
Formation of circulating 
IgA1–IgG and IgA1–IgA1 
immune complexes and 
deposition 
Immune complexes 
activate alternative 
complement pathway 
common genetic variants ITGAM is essential for interactions between CD89 and secretory IgA 
gene expression studies 
-Hyperactivation of PI3K pathway in monocytes activates FcαRI and circulating immune complexes  
aggregate this receptor.  This interaction induces shedding of the extracellular domain to form circulating 
IgA1–FcαRI complexes that could have a pathogenic role in IgAN. 
- Gene expression studies on kidney tissue have evidenced ITGAM 
4 
Local activation of 
inflammatory pathways 
and the complement 
system 
local inflammation,  
mesangial cell 
proliferation,  
secretion pro-
inflammatory 
cytokines 
leading to the 
interstitial infiltration 
of inflammatory cells 
and  promoting 
glomerular and 
tubulointerstitial 
fibrosis 
common genetic variants 
- Glomerular inflammation is enhanced by the complement system - lectin or the alternative pathway ( 
CFHR3,1-del,  CFHR1 and CFHR3) 
- ITGAM and ITGAX encode integrins that combine to form leukocyte specific complement receptor CR3 
and CR4. These may be involved in glomerular inflammation. 
gene expression studies 
 
-Various gene expression studies conducted on kidney tissue show the involvement of relevant signalling 
pathways: Activation Complement system (ITGAX-ITGAM, C1QA, C1QB); Toll-like receptor Signalling;  NF-
kB pathway; IL-8 signalling; Production of nitric oxide and reactive oxygen species in macrophages;   
-Kidney production of cytokines (mainly IL6) promotes mesangial cell proliferation  
miRNA & metilation studies -TLR9 CNV  contributes to the deterioration of the renal function 
Proteomics 
-Low levels of UMOD peptides cause progression of renal damage 
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CVs: common variants; ; RVs: rare variants; mRNA:messenger RNA; miRNAs: microRNA; eGFR:Estimated 
Glomerular Filtration Rate; RCTs:Randomized Controlled Trials;  
 
CLINICAL FINDINGS 
Phenotypic pattern (micro/macro-
hematuria proteinuria) 
eGFR 
Proteinuria 
Kidney biopsy (Damage score) 
PRECISION NEPHROLOGY 
• Accurate diagnosis 
• Targeted therapy 
RCTs with long-term follow-up 
(validation) 
MOLECULAR DATA 
Genomics (CVs, RVs) 
Transcriptomics (mRNA)  
Epigenomics (Methyl DNA regions, miRNAs) 
Proteomics (polypetides) 
Metabolomics (Metabolites) 
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